# EDGAR Filing Document

**Accession Number:** 0001948302
**File Stem:** 0001085037-23-000002
**Filing Date:** 2023-1
**Character Count:** 13852
**Document Hash:** bd29e1f6045867965e3fe587c6595fd6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001085037-23-000002.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0001085037-23-000002

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REPLICEL LIFE SCIENCES INC.
- **CENTRAL INDEX KEY:** 0001205059
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-79058
- **FILM NUMBER:** 23510699

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 900 - 570 GRANVILLE STREET
- **CITY:** VANCOUVER BC
- **STATE:** A1
- **ZIP:** V6C 3P1
- **BUSINESS PHONE:** 604-248-8693

**MAIL ADDRESS:**
- **STREET 1:** SUITE 900 - 570 GRANVILLE STREET
- **CITY:** VANCOUVER BC
- **STATE:** A1
- **ZIP:** V6C 3P1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEWCASTLE RESOURCES LTD.
- **DATE OF NAME CHANGE:** 20081128

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAN AMERICAN GOLD CORP
- **DATE OF NAME CHANGE:** 20040521

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRI LATERAL VENTURE CORP
- **DATE OF NAME CHANGE:** 20021109
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MACKAY JAMIE MYLES
- **CENTRAL INDEX KEY:** 0001948302

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**MAIL ADDRESS:**
- **STREET 1:** PO BOX 1749
- **CITY:** WILSON
- **STATE:** WY
- **ZIP:** 83014

#### UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549

#### SCHEDULE 13D/A<br> (Amendment No. 1)
Under the Securities Exchange Act of 1934<br>

---

| |
|:---|
| **REPLICEL LIFE SCIENCES INC.** |
| (Name of Issuer) |

---

---

| |
|:---|
| **Common Shares without par value** |
| (Title of Class of Securities) |

---

---

| |
|:---|
| **76027P400** |
| (CUSIP Number) |

---

---

| |
|:---|
| **copy to:**<br> **Jamie Mackay<br> P.O. Box 1749<br> Wilson, WY 83014<br> 307.414.3131** |
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |

---

---

| |
|:---|
| **December 30, 2022** |
| (Date of Event which Requires Filing of this Statement) |

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

#### SCHEDULE 13D

---

| | |
|:---|:---|
| **CUSIP No.** | **76027P400** |

---

---

| | | |
|:---|:---|:---|
| **1** | NAMES OF REPORTING PERSONS<br> I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | NAMES OF REPORTING PERSONS<br> I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) |
| **1** | Andrew Schutte | Andrew Schutte |
| **2** | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP\* |
| **2** | &nbsp;&nbsp;&nbsp;&nbsp;(a) [ ]<br> &nbsp;&nbsp;&nbsp;&nbsp;(b) [ ] | &nbsp;&nbsp;&nbsp;&nbsp;(a) [ ]<br> &nbsp;&nbsp;&nbsp;&nbsp;(b) [ ] |
| **3** | SEC USE ONLY | SEC USE ONLY |
| **3** |  |  |
| **4** | SOURCE OF FUNDS (See Instructions) | SOURCE OF FUNDS (See Instructions) |
| **4** | PF | PF |
| **5** | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) |
| **5** | [ ] | [ ] |
| **6** | CITIZENSHIP OR PLACE OF ORGANIZATION | CITIZENSHIP OR PLACE OF ORGANIZATION |
| **6** | United States | United States |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **7** | SOLE VOTING POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **7** | 8864037<sup>(1)</sup> |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **8** | SHARED VOTING POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **8** | Nil |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **9** | SOLE DISPOSITIVE POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **9** | 8864037<sup>(1)</sup> |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **10** | SHARED DISPOSITIVE POWER |
| NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | **10** | Nil |
| **11** | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| **11** | 8,864,037 common shares<sup>(1)</sup> | 8,864,037 common shares<sup>(1)</sup> |
| **12** | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) |
| **12** | [ ] | [ ] |
| **13** | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
| **13** | 16.41%<sup>(2)</sup> | 16.41%<sup>(2)</sup> |
| **14** | TYPE OF REPORTING PERSON (See Instructions) | TYPE OF REPORTING PERSON (See Instructions) |
| **14** | IN | IN |

---

<sup>(1)</sup> Consists of the following securities: (i) 6,013,037 common shares held directly; and (ii) 2,851,000 warrants each of which is exercisable into one common share, of which 1,117,917 are exercisable at a price of $0.36 per common share until July 15, 2023, 1,058,083 are exercisable at a price of $0.40 per common share until May 4, 2025 and 675,000 are exercisable at a price of $0.20 per common share until December 30, 2025.

<sup>(2)</sup> Calculated based on the aggregate of 54,020,215 common shares, which consists of: (i) 51,169,215 common shares outstanding as of December 30, 2022; and (ii) 2,851,000 common shares that may be issuable on exercise of warrants, all within sixty days, pursuant to Rule 13d-3 of the Act.

#### <br>

------

**This Schedule 13D is being filed on behalf of Jamie Mackay (the "Reporting Person") relating to the common shares of RepliCel Life Sciences Inc., a corporation existing under the laws of the Province of British Columbia (the "Issuer").**

#### Item 1. Security and Issuer
This Statement relates to the common shares (the "Shares") of the Issuer. The principal executive offices of the Issuer are located at 900 – 570 Granville Street, Vancouver, BC V6C 3P1.

#### Item 2. Identity and Background
This Statement is filed by the Reporting Person.

The Reporting Person, a director of the Issuer, has a residence address at P.O. Box 1749, Wilson, WY 83014 and is a citizen of the United States.

The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

#### Item 3. Source and Amount of Funds or Other Considerations
Pursuant to a subscription agreement dated December 30, 2022, the Reporting Person purchased 1,350,000 units (each, a "Unit") of the Issuer at a price of CDN$0.10 per Unit in a private transaction for total consideration CDN$135,000. Each Unit consists of one Share and one-half of one non-transferable share purchase warrant (each, a "Warrant"). Each Warrant entitles the Reporting Person to acquire one Share (each, a "Warrant Share") at a price of CDN$0.20 per Warrant Share until December 30, 2025.

#### Item 4. Purpose of Transaction
The Reporting Person acquired the securities for investment purposes, but may transfer or sell such Shares as necessary and in accordance with applicable securities laws.

As of the date hereof, except as described in this Schedule 13D, the Reporting Person does not have any plans or proposals which relate to or would result in:

• the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

• an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

• a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

• any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors
 or to fill any existing vacancies on the board;

• any material change in the present capitalization or dividend policy of the Issuer;

• any other material change in the Issuer's business or corporate structure, including but not limited to, if the Issuer is a registered closed-end
 investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

• changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the
 Issuer by any person;

• causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an
 inter-dealer quotation system of a registered national securities association;

• a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

• any action similar to any of those enumerated above.

#### <br>

------

#### Item 5. Interest in Securities of the Issuer
The aggregate number and percentage of Shares beneficially owned by the Reporting Person is 8,864,037 Shares (including: (i) 6,013,037 Shares held directly; and (ii) 2,851,000 warrants each of which is exercisable into one Share, of which 1,117,917 are exercisable at a price of $0.36 per Share until July 15, 2023, 1,058,083 are exercisable at a price of $0.40 per Share until May 4, 2025 and 675,000 are exercisable at a price of $0.20 per common share until December 30, 2025), or 16.41% of the Issuer, based on 54,020,215 Shares outstanding as of December 30, 2022, which consists of: (i) 51,169,215 Shares outstanding as of December 30, 2022, and (ii) 2,851,000 Shares that may be issuable on exercise of warrants, all within sixty days, pursuant to Rule 13d-3 of the Act.

The Reporting Person has the sole power to vote or direct the vote, and to dispose or direct the disposition, of 8,864,037 Shares.

Other than as described in Item 3 above, the Reporting Person has not effected any transaction in the Shares in the past sixty days.

No person, other than the Reporting Person, is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the 8,864,037 Shares.

#### Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Except as set forth above or set forth in the exhibits and this Schedule 13D, there are no contracts, arrangements, understandings or relationships between reporting persons and any other person with respect to any securities of the Issuer.

#### Item 7. Material to Be Filed as Exhibits
None.

#### Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | |
|:---|:---|
| Dated: January 5, 2023 | /s/ Jamie Mackay&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> Signature |
|  | <br> Jamie Mackay&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br> Name |

---

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

#### Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
<br>